From Bio프롬바이오

From Bio's shares have fallen sharply over the past year while losses have deepened and the company faces a market-cap-related listing warning.

From Bio sells health supplements and cosmetics, mainly through TV home shopping and online channels. Its trailing revenue of about ₩71.6B is roughly flat, but operating losses of about ₩16.3B and negative free cash flow of about ₩8.5B show the business is currently loss-making. The share price closed at ₩1,929 on 2026-10-27, down 73.6% over one year, with a market cap of about ₩10.9B.

What stands out

• Trailing twelve-month operating margin is -22.7% and net margin is -28.1%, with net losses in every year from 2023 to 2025 shown in the data.
• Revenue was ₩72.2B in 2025, up 7.4%, after a 0.7% rise in 2024 and a 32.8% fall in 2023, so top-line growth has been inconsistent.
• Liabilities are 186.8% of equity, and cash of about ₩0.76B is well below borrowings of ₩1.8B.
• Foreign ownership fell from 1.9% to 0% over the past 60 days, and the 20-day flows show foreign and institutional net selling with retail net buying.
• The data shows no dividend and no earnings-based valuation (P/E is not available), while price-to-book is 0.5.

What to watch

• A filing on 2026-09-16 notes a possible designation as an administrative issue because market cap is below ₩20B; the data does not say whether this has been decided.
• Shareholders' meeting notices were filed in October 2026; check the agenda for any capital or management changes.
• A Chosun Biz report from 2026-10-13 said the controlling shareholder is pursuing a management rights sale after a hair loss drug development setback; the data does not confirm the outcome.